Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation

Biochemistry

Volumn 47, Issue 29, 2008, Pages 7695-7705

  Nieva, Jorge ^a   Shafton, Asher ^a   Altobell III, Laurence J ^a   Tripuraneni, Sangeetha ^a   Rogel, Joseph K ^a   Wentworth, Anita D ^a   Lerner, Richard A ^a   Wentworth Jr , Paul ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATES; ALDEHYDES; AZO DYES; CHAINS; CHEMICAL REACTIONS; CONCENTRATION (PROCESS); DEPOSITS; GLYCOPROTEINS; MONOMERS; NEUROLOGY; ORGANIC COMPOUNDS; POLYMERS; SELF ASSEMBLED MONOLAYERS; THEOREM PROVING; TURBIDITY;

4-HYDROXY-NONENAL; AGGREGATION PROCESSING; AMERICAN CHEMICAL SOCIETY (ACS); AMORPHOUS AGGREGATION; AMYLOID FIBRILS; BINDING ASSAYS; CONCENTRATION DEPENDENCES; CONFORMATIONAL CHANGES; CONGO RED (CR); GLYOXAL; GROWTH PHASE; IN DEPTH STUDIES; IN-VITRO; IN-VIVO; KINETIC PROFILES; LAG PHASE; LIGHT CHAIN (LC); LOCAL ENVIRONMENTS; MALONDIALDEHYDE (MDA); MOLECULAR FACTORS; NUCLEATED POLYMERIZATION; OSMOLYTE; PATHOLOGICAL CONDITIONS; PRIMARY STRUCTURES; PROTEIN MISFOLDING; PROTEIN SECONDARY STRUCTURES; PROTEIN SEQUENCING; RENAL TISSUES; THIOFLAVIN; TRIMETHYLAMINE N-OXIDE (TMAO);

AGGLOMERATION;

4 HYDROXYNONENAL; 5,6 SECOSTEROL; ALDEHYDE DERIVATIVE; AMYLOID; ATHERONAL A; ATHERONAL B; CONGO RED; GLYOXAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; LIPID; MALONALDEHYDE; STEROL DERIVATIVE; THIOFLAVINE; TRIMETHYLAMINE OXIDE;

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; GROWTH CURVE; HUMAN; IMMUNOGLOBULIN DEPOSITION; KINETICS; LIGHT CHAIN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; TRANSMISSION ELECTRON MICROSCOPY; TURBIDITY;

ALDEHYDES; CHOLESTEROL; CONGO RED; GLYOXAL; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LIPIDS; MALONDIALDEHYDE; PROTEIN DENATURATION; THIAZOLES;

EID: 47649090153     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi800333s     Document Type: Article

References (56)

1. Buxbaum, J. (1992) Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol. Oncol. Clin. North Am. 6, 323-346.
2. Buxbaum, J. N., Chuba, J. V., Hellman, G. C., Solomon, A., and Gallo, G. R. (1990) Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann. Intern. Med. 112, 455-464.
3. Pelegri, A., Campo, E., Romero, R., Reguant, M., and Aisa, L. (1986) AL-type amyloidosis and light chain deposition disease. Clin. Nephrol. 25, 220.
4. Gertz, M. A., Lacy, M. Q., and Dispenzieri, A. (1999) Amyloidosis. Hematol. Oncol. Clin. North Am. 6, 1211-1233.
5. Glenner, G. G., Harbaugh, J., Ohms, J. I., Harada, M., and Cuatrecasas, P. (1970) An amyloid protein: the amino-terminal variable fragment of an immunoglobulin light chain. Biochem. Biophys. Res. Commun. 41, 1287-1289.
6. Glenner, G. G. (1980) Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N. Engl. J. Med. 302, 1283-1292.
7. Bellotti, V., Mangione, P., and Merlini, G. (2000) Review: immunoglobulin light chain amyloidosis-the archetype of structural and pathogenic variability. J. Struct. Biol. 130, 280-289.
8. Hsu, J. Y., Shu, K. H., Chan, L. P., Lu, Y. S., Cheng, C. H., Sheu, S. S., and Lian, J. D. (1994) The clinicopathological spectrum of renal amyloidosis. Zhonghua Yixue Zazhi (Taipei, Taiwan) 54, 230-239.
9. Preud'homme, J. L., Aucouturier, P., Touchard, G., Khamlichi, A. A., Rocca, A., Denoroy, L., and Cogne, M. (1994) Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. Int. J. Immunopharmacol. 16, 425-431.
10. Kyle, R. A. (1989) Monoclonal gammopathies and the kidney. Annu. Rev. Med. 40, 53-60.
11. Solomon, A., Weiss, D. T., and Wall, J. S. (2003) Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother. Radiopharm. 18, 853-860.
12. Gallo, G., Picken, M., Buxbaum, J., and Frangione, B. (1989) unknown. Semin. Hematol. 26, 234-245.
13. Ganeval, D., Nöel, L.-H., Preud'homme, J. L., Droz, D., and Grünfeld, J.-P. (1984) unknown. Kidney Int. 26, 1-9.
14. Kaplan, B., Vidal, R., Kumar, A., Ghiso, J., Frangione, B., and Gallo, G. (1997) Amino-terminal identity of co-existent amyloid and non-amyloid immunoglobulin kappa light chain deposits. A human disease to study alterations of protein conformation. Clin. Exp. Immunol. 110, 472-478.
15. Wall, J., Schell, M., Murphy, C., Hrncic, R., Stevens, F. J., and Solomon, A. (1999) Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38, 14101-14108.
16. Ozaki, S., Abe, M., Wolfenbarger, D., Weiss, D. T., and Solomon, A. (1994) Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. Clin. Immunol. Immunopathol. 71, 183-189.
17. Solomon, A., and Weiss, D. T. (1987) Serologically defined V region subgroups of human lambda light chains. J. Immunol. 139, 824-830.
18. Hurle, M. R., Helms, L. R., Li, L., Chan, W., and Wetzel, R. (1994) A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 91, 5446-5450.
19. Stevens, F. J., and Kisilevsky, R. (2000) Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell. Mol. Life Sci. 57, 441-449.
20. Wentworth, P., Jr., Nieva, J., Takeuchi, C., Galve, R., Wentworth, A. D., Dilley, R. B., DeLaria, G. A., Saven, A., Babior, B. M., Janda, K. D., Eschenmoser, A., and Lerner, R. A. (2003) Evidence for ozone formation in human atherosclerotic arteries. Science 302, 1053-1056.
21. Zhang, Q., Powers, E. T., Nieva, J., Huff, M. E., Dendle, M. A., Bieschke, J., Glabe, C. G., Eschenmoser, A., Wentworth, P., Jr., Lerner, R. A., and Kelly, J. W. (2004) Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 4752-4757.
22. Scheinost, J. C., Wang, H., Boldt, G. E., Offer, J., and Wentworth, P. J. (2008) Cholesterol seco-sterol-induced aggregation of methylated amyloid-102 peptides - Insights into aldehyde-initiated fibrillization of amyloid-β, Angew. Chem., Int. Ed. (in press).
23. Bosco, D. A., Fowler, D., Zhang, Q., Nieva, J., Powers, E. T., Wentworth, J., P., Lerner, R. A., and Kelly, J. W. (2006) Toxic cholesterol metabolites that are elevated in Lewy body disease brains accelerate alpha-synuclein fibrillization in vitro. Nat. Chem. Biol. 2, 249-253.
24. Matsuoka, Y., Yagi, Y., Moore, G. E., and Pressman, D. (1969) Isolation and characterization of free lambda-chain of immunoglobulin produced by an established cell line of human myeloma cell origin. II. Identity of lambda-chains in cells and in medium. J. Immunol. 103, 962-969.
25. Moore, G. E., and Kitamura, H. (1968) Cell line derived from patient with myeloma. N.Y. State J. Med. 68, 2054-2060.
26. Klunk, W. E., Jacob, R. F., and Mason, R. P. (1999) Quantifying amyloid β-peptide (aβ) aggregation using the Congo Red-Aβ (CR-Aβ) spectrophotometric assay. Anal. Biochem. 266, 66-76.
27. Lobley, A., and Wallace, B. A. (2001) DICHROWEB: a website for the analysis if protein secondary structure from circular dichroism spectra. Biophys. J. 80, 373a.
28. Lobley, A., Whitmore, L., and Wallace, B. A. (2002) DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 18, 211-212.
29. Manavalan, P., and Johnson, W. C. J. (1986) Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra. Anal. Biochem. 167, 76-85.
30. Sreerema, N., and Woody, R. W. (1993) A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal. Biochem. 209, 32-44.
31. LeVine, I. I. I. H., and Ronald, W. (1999) Quantification of β-sheet amyloid fibril structures with thioflavin T, in Methods in Enzymology, pp 274-284, Academic Press, New York.
32. Hurshman, A. R., White, J. T., Powers, E. T., and Kelly, J. W. (2004) Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43, 7365-7381.
33. Ferrone, F. (1999) Analysis of protein aggregation kinetics. Methods Enzymol. 309, 256-274.
34. Oosawa, F., and Asakura, S. (1975) Thermodynamics of the Polymerization of Protein, Academic Press, London.
35. Kihara, M., Chatani, E., Sakai, M., Hasegawa, K., Naiki, H., and Goto, Y. (2005) Seeding-dependent maturation of beta2-microglobulin amyloid fibrils at neutral pH. J. Biol. Chem. 280, 12012-12018.
36. Perlmutter, D. H. (2002) Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking. Pediatr. Res. 52, 832-836.
37. Tazelt, J., Prusiner, S. B., and Welch, W. J. (1996) Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J. 15, 6363-6373.
38. Bennion, B. J., DeMarco, M. L., and Daggert, V. (2004) Preventing misfolding of the prion protein by trimethylamine N-oxide. Biochemistry 43, 12595-12963.
39. Esterbauer, H. (1982) Lipid peroxidation products: formation, chemical properties and biological activities, in Free Radical in Liver Injury (Poli, G., Cheeseman, K. H., Dianzani, M. U., and Slater, T. F., Eds.) pp29-47, IRL Press, Oxford.
40. Benedetti, A., Comporti, M., and Esterbauer, H. (1980) Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim. Biophys. Acta 620, 281-296.
41. Zarkovic, K. (2003) 4-Hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 24, 293-303.
42. Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Guglielmotto, M., Santoro, G., Davit, A., Danni, O., Smith, M. A., Perry, G., and Tabaton, M. (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92, 628-636.
43. 2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180, 144-155.
44. Leonarduzzi, G., Robbesyn, F., and Poli, G. (2004) Signaling kinases modulated by 4-hydroxynonenal. Free Radical Biol. Med. 37, 1694-1702.
45. Escargueil-Blanc, I., Salvayre, R., Vacaresse, N., Jurgens, G., Darblade, B., Arnal, J.-F., Parthasarathy, S., and Negre-Salvayre, A. (2001) Mildly oxidized LDL induces activation of platelet-derived growth factor β-receptor pathway. Circulation 104, 1814-1821.
46. McGrath, L. T., McGleenon, B. M., Brennan, S., McColl, D., McIlroy, S., and Passmore, A. P. (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM: Mon. J. Assoc. Physicians 94, 485-490.
47. Grune, T., Michel, P., Sitte, N., Eggert, W., Albrecht-Nebe, H., Esterbauer, H., and Siems, W. (1997) Increased levels of 4-hydroxynonenal modified proteins in plasma of children with autoimmune diseases. Free Radical Biol. Med. 23, 357-360.
48. Przekwas, M., Malgorzewicz, S., Zdrojewski, Z., Debska-Slizien, A., Lysiak-Szydlowska, W., and Rutkowski, B. (2003) Influence of predialysis oxidative stress on peroxidation processes after renal transplantation. Transplant Proc. 35, 2170-2173.
49. Esterbauer, H., Zollner, H., and Schaur, R. J. (1990) Aldehydes formed by lipid peroxidation: mechanisms of formation, occurrence, and determination, in Membrane Lipid Oxidation (Vigo-Pelfrey, C., Ed.) pp239-268, CRC Press, Boston, MA.
50. Buxbaum, J. N. (2003) Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? Trends Biochem. Sci. 28, 585-592.
51. Khurana, R., and Fink, A. L. (2000) Do parallel beta-helix proteins have a unique Fourier transform infrared spectrum? Biophys. J. 78, 994-1000.
52. Souillac, P. O., Uversky, V. N., Millett, I. S., Khurana, R., Doniach, S., and Fink, A. L. (2002) Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off-pathway oligomer at acidic pH. J. Biol. Chem. 277, 12666-12679.
53. Booth, D. R., Sunde, M., Belloti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C. F., and Pepys, M. B. (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793.
54. Wetzel, R. (1996) For protein misassembly, it's the I decade. Cell 86, 699-702.
55. Khurana, R., Gillespie, J. R., Talapatra, A., Minert, L. J., Ionescu-Zaneti, C., Millett, I., and Fink, A. L. (2001) Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 40, 3525-3535.
56. Jiang, X., Myatt, E., Lykos, P., and Stevens, F. J. (1997) Interaction between glycosaminoglycans and immunoglobulin light chains. Biochemistry 36, 13187-13194.